Histological Analysis of Osteogenic Potential of Biphasic Calcium Phosphate
Alveolar Ridge Enlargement, Fenestration, Dehiscence
About this trial
This is an interventional treatment trial for Alveolar Ridge Enlargement focused on measuring bone regeneration, alloplast, bovine xenograft, guided bone regeneration
Eligibility Criteria
Inclusion Criteria: age between 18 and 60 years patients requires to have at least one tooth predisposed to extraction intact physical and mental health patient must understand the study protocol patient must sign an informed consent. the presence of a buccal bone defect such as fenestration or dehiscence. Exclusion Criteria: patients will be excluded from the study if they had at least one of the absolute contraindications to implant prosthetic therapy following systemic diseases: uncontrolled diabetes, osteoporosis and osteopenia, and vitamin D deficiency bisphosphonate therapy glucocorticoid therapy hypothyroidism uncontrolled cardiovascular disease (hypertension, coronary artery disease, congestive heart failure) pregnant or lactating women following local factors: use of tobacco products (up to 10 cigarettes per day) and poor oral hygiene
Sites / Locations
- Faculty of Medicine Osijek
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Injectable biphasic calcium phosphate (maxresorb inject, botiss GmbH)
Bovine xenograft (cerabone, botiss GmbH)
This biomaterial is an alloplastic bone substitute material in the form of a paste that is placed into the defect with a plastic syringe. The material consists of an aqueous gel containing granules of biphasic calcium phosphate in the composition of 60% HA and 40% β-TCP (particle size between 15-50 nm).
The material is completely anorganic and consists of 100% HA. For this study, the material will be used in granular form (the size of the granules is between 0.5 and 1 mm), mixed with physiological solution prior to placement into the defect.